BioVie, Inc. Common Stock (BIVI)
BioVie, Inc. is a biotech company focused on developing innovative therapies for neurodegenerative and liver diseases. The company is known for its research into drug candidates aimed at addressing unmet medical needs, particularly in conditions such as hepatic encephalopathy. BioVie's approach involves leveraging novel mechanisms and proprietary formulations to create impactful treatments.
Company News
BioVie Inc. has priced a public offering of 6 million units at $2.00 per unit, expecting to raise approximately $12 million. The offering includes common stock and warrants, with proceeds intended for working capital and general corporate purposes.
BioVie Inc. is pricing a public offering of 6 million units, each consisting of one common stock share and one warrant, expected to raise approximately $12 million for working capital and general corporate purposes.
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's 3 habits for penny stocks traders to use in 2024 The post Top Habits Penny Stocks Traders Need to Follow appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Misconduct issues were identified in several BioVie trial sites, leading to exclusion of majority of enrolled patients and a severely underpowered study. Read more here.